1
|
di Franco F, Rosuel N, Gallin-Martel L, Gallin-Martel ML, Ghafooryan-Sangchooli M, Keshmiri S, Motte JF, Muraz JF, Pellicioli P, Ruat M, Serduc R, Verry C, Dauvergne D, Adam JF. Monocrystalline diamond detector for online monitoring during synchrotron microbeam radiotherapy. JOURNAL OF SYNCHROTRON RADIATION 2023; 30:1076-1085. [PMID: 37815374 PMCID: PMC10624038 DOI: 10.1107/s160057752300752x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 08/28/2023] [Indexed: 10/11/2023]
Abstract
Microbeam radiation therapy (MRT) is a radiotherapy technique combining spatial fractionation of the dose distribution on a micrometric scale, X-rays in the 50-500 keV range and dose rates up to 16 × 103 Gy s-1. Nowadays, in vivo dosimetry remains a challenge due to the ultra-high radiation fluxes involved and the need for high-spatial-resolution detectors. The aim here was to develop a striped diamond portal detector enabling online microbeam monitoring during synchrotron MRT treatments. The detector, a 550 µm bulk monocrystalline diamond, is an eight-strip device, of height 3 mm, width 178 µm and with 60 µm spaced strips, surrounded by a guard ring. An eight-channel ASIC circuit for charge integration and digitization has been designed and tested. Characterization tests were performed at the ID17 biomedical beamline of the European Synchrotron Radiation Facility (ESRF). The detector measured direct and attenuated microbeams as well as interbeam fluxes with a precision level of 1%. Tests on phantoms (RW3 and anthropomorphic head phantoms) were performed and compared with simulations. Synchrotron radiation measurements were performed on an RW3 phantom for strips facing a microbeam and for strips facing an interbeam area. A 2% difference between experiments and simulations was found. In more complex geometries, a preliminary study showed that the absolute differences between simulated and recorded transmitted beams were within 2%. Obtained results showed the feasibility of performing MRT portal monitoring using a microstriped diamond detector. Online dosimetric measurements are currently ongoing during clinical veterinary trials at ESRF, and the next 153-strip detector prototype, covering the entire irradiation field, is being finalized at our institution.
Collapse
Affiliation(s)
- Francesca di Franco
- Université Grenoble-Alpes, CNRS, Grenoble INP, LPSC UMR5821, 38000 Grenoble, France
| | - Nicolas Rosuel
- Université Grenoble-Alpes, CNRS, Grenoble INP, LPSC UMR5821, 38000 Grenoble, France
| | | | | | | | - Sarvenaz Keshmiri
- Université Grenoble-Alpes, UGA/INSERM UA7 STROBE, 2280 Rue de la Piscine, 38400 Saint-Martin d’Hères, France
| | - Jean-François Motte
- Université Grenoble-Alpes, Institut Néel, CNRS, Grenoble-INP, Grenoble, France
| | - Jean-François Muraz
- Université Grenoble-Alpes, CNRS, Grenoble INP, LPSC UMR5821, 38000 Grenoble, France
| | | | | | - Raphael Serduc
- Université Grenoble-Alpes, UGA/INSERM UA7 STROBE, 2280 Rue de la Piscine, 38400 Saint-Martin d’Hères, France
- Centre Hospitalier Universitaire Grenoble-Alpes, CS10217, 38043 Grenoble, France
| | - Camille Verry
- Centre Hospitalier Universitaire Grenoble-Alpes, CS10217, 38043 Grenoble, France
| | - Denis Dauvergne
- Université Grenoble-Alpes, CNRS, Grenoble INP, LPSC UMR5821, 38000 Grenoble, France
| | - Jean-François Adam
- Université Grenoble-Alpes, UGA/INSERM UA7 STROBE, 2280 Rue de la Piscine, 38400 Saint-Martin d’Hères, France
- Centre Hospitalier Universitaire Grenoble-Alpes, CS10217, 38043 Grenoble, France
| |
Collapse
|
2
|
Sotiropoulos M, Prezado Y. Radiation quality correction factors for improved dosimetry in preclinical minibeam radiotherapy. Med Phys 2022; 49:6716-6727. [PMID: 35904962 DOI: 10.1002/mp.15838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 06/03/2022] [Accepted: 06/19/2022] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND In reference dosimetry, radiation quality correction factors are used in order to account for changes in the detector's response among different radiation qualities, improving dosimetric accuracy. PURPOSE Reference dosimetry radiation quality corrections factors for the PTW microDiamond were calculated for preclinical X-ray and proton minibeams, and their impact in dosimetric accuracy was evaluated. METHODS A formalism for the calculation of radiation quality correction factors for absolute dosimetry in minibeam fields was developed. Following our formalism, radiation quality correction factors were calculated for the PTW microDiamond detector, using the Monte Carlo method. Models of the detector, and X-ray and proton irradiation platform, were imported into the TOPAS Monte Carlo simulation toolkit. The radiation quality correction factors were calculated in the following scenarios: (i) reference dosimetry open field to minibeam center of the central peak, (ii) different positions at the minibeam profile (along the peaks and valleys direction) to the center of the central minibeam, and (iii) some representative depth positions. In addition, the radiation quality correction factors needed for the calculation of the peak-to-valley dose ratio at different depths were calculated. RESULTS An important overestimation of the dose (about 10%) was found in the case of the open to minibeam field for both X-rays and proton beams, when the correction factors were used. Smaller differences were observed in the other cases. CONCLUSIONS The usage of the PTW microDiamond detector requires radiation quality correction factors in order to be used in minibeam reference dosimetry.
Collapse
Affiliation(s)
- Marios Sotiropoulos
- Signalisation Radiobiologie et Cancer, CNRS UMR3347, Inserm U1021, Institut Curie, Université PSL, Orsay, France
| | - Yolanda Prezado
- Signalisation Radiobiologie et Cancer, CNRS UMR3347, Inserm U1021, Institut Curie, Université PSL, Orsay, France
| |
Collapse
|
3
|
Evaluation of the clinical implementation of a tattoo-free positioning technique in breast cancer radiotherapy using ExacTrac. Phys Med 2022; 98:81-87. [DOI: 10.1016/j.ejmp.2022.04.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Revised: 02/28/2022] [Accepted: 04/27/2022] [Indexed: 11/18/2022] Open
|
4
|
Towards neuro-oncologic clinical trials of high dose rate synchrotron Microbeam Radiation Therapy: first treatment of a spontaneous canine brain tumor. Int J Radiat Oncol Biol Phys 2022; 113:967-973. [DOI: 10.1016/j.ijrobp.2022.04.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Revised: 04/13/2022] [Accepted: 04/16/2022] [Indexed: 11/22/2022]
|
5
|
Keshmiri S, Brocard S, Serduc R, Adam JF. A high resolution dose calculation engine for x-ray microbeams radiation therapy. Med Phys 2022; 49:3999-4017. [PMID: 35342953 PMCID: PMC9322281 DOI: 10.1002/mp.15637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Revised: 03/04/2022] [Accepted: 03/08/2022] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND Microbeam radiation therapy (MRT) is a treatment modality based on spatial fractionation of synchrotron generated x-rays into parallel, high dose, microbeams of a few microns width. MRT is still an under-development radiosurgery technique for which, promising preclinical results on brain tumors and epilepsy encourages its clinical transfer. PURPOSE A safe clinical transfer of MRT needs a specific treatment planning system (TPS) that provides accurate dose calculations in human patients, taking into account the MRT beams properties (high dose gradients, spatial fractionation, polarization effects). So far, the most advanced MRT treatment planning system, based on a hybrid dose calculation algorithm, is limited to a macroscopic rendering of the dose and does not account for the complex dose distribution inherent to MRT if delivered as conformal irradiations with multiple incidences. For overcoming these limitations, a multi-scale full Monte-Carlo calculation engine called penMRT has been developed and benchmarked against two general purpose Monte Carlo codes: penmain based on PENELOPE and Gate based on Geant4. METHODS PenMRT, is based on the PENELOPE (2018) Monte Carlo (MC) code, modified to take into account the voxelized geometry of the patients (CT-scans) and offering an adaptive micrometric dose calculation grid independent to the CT size, location and orientation. The implementation of the dynamic memory allocation in penMRT, makes the simulations feasible within a huge number of dose scoring bins. The possibility of using a source replication approach to simulate arrays of microbeams, and the parallelization using OpenMPI have been added to penMRT in order to increase the calculation speed for clinical usages. This engine can be implemented in a TPS as a dose calculation core. RESULTS The performance tests highlight the reliability of penMRT to be used for complex irradiation conditions in MRT. The benchmarking against a standard PENELOPE code did not show any significant difference for calculations in centimetric beams, for a single microbeam and for a microbeam array. The comparisons between penMRT and Gate as an independent MC code did not show any difference in the beam paths, whereas in valley regions, relative differences between the two codes rank from 1 to 7.5% which are probably due to the differences in physics lists that are used in these two codes. The reliability of the source replication approach has also been tested and validated with an underestimation of no more than 0.6% in low dose areas. CONCLUSIONS Good agreements (a relative difference between 0 to 8%) were found when comparing calculated peak to valley dose ratio (PVDR) values using penMRT, for irradiations with a full microbeam array, with calculated values in the literature. The high-resolution calculated dose maps obtained with penMRT are used to extract differential and cumulative dose-volume histograms (DVHs) and analyze treatment plans with much finer metrics regarding the irradiation complexity. To our knowledge, these are the first high-resolution dose maps and associated DVHs ever obtained for cross-fired microbeams irradiation, which is bringing a significant added value to the field of treatment planning in spatially fractionated radiation therapy. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
| | - Sylvan Brocard
- Univ. Grenoble Alpes, INSERM, UA07 STROBE, Grenoble, 38000, France
| | - Raphaël Serduc
- Univ. Grenoble Alpes, INSERM, UA07 STROBE, Grenoble, 38000, France.,Centre Hospitalier Universitaire de Grenoble, Grenoble, 38000, France
| | - Jean-François Adam
- Univ. Grenoble Alpes, INSERM, UA07 STROBE, Grenoble, 38000, France.,Centre Hospitalier Universitaire de Grenoble, Grenoble, 38000, France
| |
Collapse
|
6
|
Laissue JA. Elke Bräuer-Krisch: dedication, creativity and generosity: May 17, 1961-September 10, 2018. Int J Radiat Biol 2021; 98:280-287. [PMID: 34129423 DOI: 10.1080/09553002.2021.1941385] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
PURPOSE This extraordinary woman worked her professional way from a radiation protection engineer to become the successful principal investigator of a prestigious international European project for a new radiation therapy (ERC Synergy grant, HORIZON 2020). The evaluation of the submitted proposal was very positive. The panel proposed that it be funded. Elke tragically passed away a few days before this conclusion of the panel. The present account describes her gradual career development; it includes many episodes that Elke personally chronicled in her curriculum of 2017. METHODS An internet literature search was performed using Google Scholar and other sources to assist in the writing of this narrative review and account. CONCLUSIONS In parallel to the development of the new Biomedical Beamline ID17 at the European Synchrotron Radiation Facility in Grenoble in the late nineties, Elke focused her interest and her personal and professional priorities on MRT, particularly on its clinical goals. She outlined her main objectives in several documents: (1) develop a new paradigm of cancer care by broadening the foundation for MRT. (2) Filling the gaps in basic biological knowledge about the mechanisms of MRT effects on normal and neoplastic tissues. (3) Broaden the preclinical level of evidence for the low normal organ toxicity of MRT versus standard X-ray irradiations; preclinical experiments involved the application of MRT to animal tumor patients, to animals of larger size than laboratory rodents, using larger radiation field sizes, and irradiating in a real-time scenario comparable to the one planned for human patients. (4) To foster the specific purpose of radiosurgical MRT of tumor patients at the ESRF that required development of new, specific state of the art modalities and tools for treatment planning, dosimetry, dose calculation, patient positioning and, of particular importance, redundant levels of patient safety. Just as she was about to take responsibility as principal investigator for a prestigious international European project on a new radiation therapy, death called Elke in.
Collapse
Affiliation(s)
- Jean A Laissue
- Institute of Pathology, University of Bern, Bern, Switzerland
| |
Collapse
|
7
|
Piffer S, Casati M, Marrazzo L, Arilli C, Calusi S, Desideri I, Fusi F, Pallotta S, Talamonti C. Validation of a secondary dose check tool against Monte Carlo and analytical clinical dose calculation algorithms in VMAT. J Appl Clin Med Phys 2021; 22:52-62. [PMID: 33735491 PMCID: PMC8035572 DOI: 10.1002/acm2.13209] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Revised: 01/21/2021] [Accepted: 02/02/2021] [Indexed: 11/18/2022] Open
Abstract
PURPOSE Patient-specific quality assurance (QA) is very important in radiotherapy, especially for patients with highly conformed treatment plans like VMAT plans. Traditional QA protocols for these plans are time-consuming reducing considerably the time available for patient treatments. In this work, a new MC-based secondary dose check software (SciMoCa) is evaluated and benchmarked against well-established TPS (Monaco and Pinnacle3 ) by means of treatment plans and dose measurements. METHODS Fifty VMAT plans have been computed using same calculation parameters with SciMoCa and the two primary TPSs. Plans were validated with measurements performed with a 3D diode detector (ArcCHECK) by translating patient plans to phantom geometry. Calculation accuracy was assessed by measuring point dose differences and gamma passing rates (GPR) from a 3D gamma analysis with 3%-2 mm criteria. Comparison between SciMoCa and primary TPS calculations was made using the same estimators and using both patient and phantom geometry plans. RESULTS TPS and SciMoCa calculations were found to be in very good agreement with validation measurements with average point dose differences of 0.7 ± 1.7% and -0.2 ± 1.6% for SciMoCa and two TPSs, respectively. Comparison between SciMoCa calculations and the two primary TPS plans did not show any statistically significant difference with average point dose differences compatible with zero within error for both patient and phantom geometry plans and GPR (98.0 ± 3.0% and 99.0 ± 3.0% respectively) well in excess of the typical 95 % clinical tolerance threshold. CONCLUSION This work presents results obtained with a significantly larger sample than other similar analyses and, to the authors' knowledge, compares SciMoCa with a MC-based TPS for the first time. Results show that a MC-based secondary patient-specific QA is a clinically viable, reliable, and promising technique, that potentially allows significant time saving that can be used for patient treatment and a per-plan basis QA that effectively complements traditional commissioning and calibration protocols.
Collapse
Affiliation(s)
- Stefano Piffer
- Department of Experimental and Clinical Biomedical SciencesUniversity of FlorenceFlorenceItaly
- National Institute of Nuclear Physics (INFN)FlorenceItaly
| | - Marta Casati
- Department of Medical PhysicsCareggi University HospitalFlorenceItaly
| | - Livia Marrazzo
- Department of Medical PhysicsCareggi University HospitalFlorenceItaly
| | - Chiara Arilli
- Department of Medical PhysicsCareggi University HospitalFlorenceItaly
| | - Silvia Calusi
- Department of Experimental and Clinical Biomedical SciencesUniversity of FlorenceFlorenceItaly
| | - Isacco Desideri
- Department of Experimental and Clinical Biomedical SciencesUniversity of FlorenceFlorenceItaly
| | - Franco Fusi
- Department of Experimental and Clinical Biomedical SciencesUniversity of FlorenceFlorenceItaly
| | - Stefania Pallotta
- Department of Experimental and Clinical Biomedical SciencesUniversity of FlorenceFlorenceItaly
- National Institute of Nuclear Physics (INFN)FlorenceItaly
- Department of Medical PhysicsCareggi University HospitalFlorenceItaly
| | - Cinzia Talamonti
- Department of Experimental and Clinical Biomedical SciencesUniversity of FlorenceFlorenceItaly
- National Institute of Nuclear Physics (INFN)FlorenceItaly
- Department of Medical PhysicsCareggi University HospitalFlorenceItaly
| |
Collapse
|
8
|
Pellicioli P, Donzelli M, Davis JA, Estève F, Hugtenburg R, Guatelli S, Petasecca M, Lerch MLF, Bräuer-Krisch E, Krisch M. Study of the X-ray radiation interaction with a multislit collimator for the creation of microbeams in radiation therapy. JOURNAL OF SYNCHROTRON RADIATION 2021; 28:392-403. [PMID: 33650550 DOI: 10.1107/s1600577520016811] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Accepted: 12/31/2020] [Indexed: 06/12/2023]
Abstract
Microbeam radiation therapy (MRT) is a developing radiotherapy, based on the use of beams only a few tens of micrometres wide, generated by synchrotron X-ray sources. The spatial fractionation of the homogeneous beam into an array of microbeams is possible using a multislit collimator (MSC), i.e. a machined metal block with regular apertures. Dosimetry in MRT is challenging and previous works still show differences between calculated and experimental dose profiles of 10-30%, which are not acceptable for a clinical implementation of treatment. The interaction of the X-rays with the MSC may contribute to the observed discrepancies; the present study therefore investigates the dose contribution due to radiation interaction with the MSC inner walls and radiation leakage of the MSC. Dose distributions inside a water-equivalent phantom were evaluated for different field sizes and three typical spectra used for MRT studies at the European Synchrotron Biomedical beamline ID17. Film dosimetry was utilized to determine the contribution of radiation interaction with the MSC inner walls; Monte Carlo simulations were implemented to calculate the radiation leakage contribution. Both factors turned out to be relevant for the dose deposition, especially for small fields. Photons interacting with the MSC walls may bring up to 16% more dose in the valley regions, between the microbeams. Depending on the chosen spectrum, the radiation leakage close to the phantom surface can contribute up to 50% of the valley dose for a 5 mm × 5 mm field. The current study underlines that a detailed characterization of the MSC must be performed systematically and accurate MRT dosimetry protocols must include the contribution of radiation leakage and radiation interaction with the MSC in order to avoid significant errors in the dose evaluation at the micrometric scale.
Collapse
Affiliation(s)
- P Pellicioli
- ID17 Biomedical Beamline, ESRF - The European Synchrotron, 71 avenue des Martyrs, Grenoble, France
| | - M Donzelli
- ID17 Biomedical Beamline, ESRF - The European Synchrotron, 71 avenue des Martyrs, Grenoble, France
| | - J A Davis
- School of Physics, University of Wollongong, Wollongong, Australia
| | - F Estève
- STROBE - Synchrotron Radiation for Biomedicine, Grenoble, France
| | - R Hugtenburg
- Swansea University Medical School, Singleton Park, Swansea, United Kingdom
| | - S Guatelli
- School of Physics, University of Wollongong, Wollongong, Australia
| | - M Petasecca
- School of Physics, University of Wollongong, Wollongong, Australia
| | - M L F Lerch
- School of Physics, University of Wollongong, Wollongong, Australia
| | - E Bräuer-Krisch
- ID17 Biomedical Beamline, ESRF - The European Synchrotron, 71 avenue des Martyrs, Grenoble, France
| | - M Krisch
- ID17 Biomedical Beamline, ESRF - The European Synchrotron, 71 avenue des Martyrs, Grenoble, France
| |
Collapse
|
9
|
Schültke E, Fiedler S, Menk RH, Jaekel F, Dreossi D, Casarin K, Tromba G, Bartzsch S, Kriesen S, Hildebrandt G, Arfelli F. Perspectives for microbeam irradiation at the SYRMEP beamline. JOURNAL OF SYNCHROTRON RADIATION 2021; 28:410-418. [PMID: 33650552 PMCID: PMC7941286 DOI: 10.1107/s1600577521000400] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Accepted: 01/12/2021] [Indexed: 05/10/2023]
Abstract
It has been shown previously both in vitro and in vivo that microbeam irradiation (MBI) can control malignant tumour cells more effectively than the clinically established concepts of broad beam irradiation. With the aim to extend the international capacity for microbeam research, the first MBI experiment at the biomedical beamline SYRMEP of the Italian synchrotron facility ELETTRA has been conducted. Using a multislit collimator produced by the company TECOMET, arrays of quasi-parallel microbeams were successfully generated with a beam width of 50 µm and a centre-to-centre distance of 400 µm. Murine melanoma cell cultures were irradiated with a target dose of approximately 65 Gy at a mean photon energy of ∼30 keV with a dose rate of 70 Gy s-1 and a peak-to-valley dose of ∼123. This work demonstrated a melanoma cell reduction of approximately 80% after MBI. It is suggested that, while a high energy is essential to achieve high dose rates in order to deposit high treatment doses in a short time in a deep-seated target, for in vitro studies and for the treatment of superficial tumours a spectrum in the lower energy range might be equally suitable or even advantageous.
Collapse
Affiliation(s)
- Elisabeth Schültke
- Department of Radiooncology, Rostock University Medical Center, Südring 75, 18059 Rostock, Germany
| | - Stefan Fiedler
- European Molecular Biology Laboratory, Notkestrasse 85, 22607 Hamburg, Germany
| | - Ralf Hendrik Menk
- Elettra-Sincrotrone Trieste, Strada Statale 14, Trieste 34149, Italy
- University of Saskatchewan, Saskatoon, Saskatchewan, Canada
- Trieste Section, Istituto Nazionale Fisica Nucleare (INFN), Trieste, Italy
| | - Felix Jaekel
- Department of Radiooncology, Rostock University Medical Center, Südring 75, 18059 Rostock, Germany
| | - Diego Dreossi
- Elettra-Sincrotrone Trieste, Strada Statale 14, Trieste 34149, Italy
| | - Katia Casarin
- Elettra-Sincrotrone Trieste, Strada Statale 14, Trieste 34149, Italy
| | - Giuliana Tromba
- Elettra-Sincrotrone Trieste, Strada Statale 14, Trieste 34149, Italy
| | - Stefan Bartzsch
- Department of Radiooncology, Technical University Munich, Munich, Germany
- Institute for Innovative Radiotherapy, Helmholtz-Zentrum Munich (HMGU), Munich, Germany
| | - Stephan Kriesen
- Department of Radiooncology, Rostock University Medical Center, Südring 75, 18059 Rostock, Germany
| | - Guido Hildebrandt
- Department of Radiooncology, Rostock University Medical Center, Südring 75, 18059 Rostock, Germany
| | - Fulvia Arfelli
- Trieste Section, Istituto Nazionale Fisica Nucleare (INFN), Trieste, Italy
- Department of Physics, University of Trieste, Trieste, Italy
| |
Collapse
|
10
|
Unexpected Benefits of Multiport Synchrotron Microbeam Radiation Therapy for Brain Tumors. Cancers (Basel) 2021; 13:cancers13050936. [PMID: 33668110 PMCID: PMC7956531 DOI: 10.3390/cancers13050936] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 02/05/2021] [Accepted: 02/08/2021] [Indexed: 11/17/2022] Open
Abstract
Simple Summary We unveiled the potential of an innovative irradiation technique that ablates brain cancer while sparing normal tissues. Spatially fractionating the incident beam into arrays of micrometer-wide beamlets of X-rays (MRT for Microbeam Radiation Therapy) has led to significantly increased survival and tumor control in preclinical studies. Multiport MRT versus conventional irradiations, for the same background continuous dose, resulted in unexpectedly high equivalent biological effects in rats that have not been achieved with any other radiotherapeutic method. These hallmarks of multiport MRT, i.e., minimal impact on normal tissues and exceptional tumor control, may promote this method towards clinical applications, possibly increasing survival and improving long-term outcomes in neuro-oncology patients. Abstract Delivery of high-radiation doses to brain tumors via multiple arrays of synchrotron X-ray microbeams permits huge therapeutic advantages. Brain tumor (9LGS)-bearing and normal rats were irradiated using a conventional, homogeneous Broad Beam (BB), or Microbeam Radiation Therapy (MRT), then studied by behavioral tests, MRI, and histopathology. A valley dose of 10 Gy deposited between microbeams, delivered by a single port, improved tumor control and median survival time of tumor-bearing rats better than a BB isodose. An increased number of ports and an accumulated valley dose maintained at 10 Gy delayed tumor growth and improved survival. Histopathologically, cell death, vascular damage, and inflammatory response increased in tumors. At identical valley isodose, each additional MRT port extended survival, resulting in an exponential correlation between port numbers and animal lifespan (r2 = 0.9928). A 10 Gy valley dose, in MRT mode, delivered through 5 ports, achieved the same survival as a 25 Gy BB irradiation because of tumor dose hot spots created by intersecting microbeams. Conversely, normal tissue damage remained minimal in all the single converging extratumoral arrays. Multiport MRT reached exceptional ~2.5-fold biological equivalent tumor doses. The unique normal tissue sparing and therapeutic index are eminent prerequisites for clinical translation.
Collapse
|